ID30138A - Penghambat-penghambat trisiklik dari poli (adp-ribose) polimesase - Google Patents

Penghambat-penghambat trisiklik dari poli (adp-ribose) polimesase

Info

Publication number
ID30138A
ID30138A IDW00200101726A ID20011726A ID30138A ID 30138 A ID30138 A ID 30138A ID W00200101726 A IDW00200101726 A ID W00200101726A ID 20011726 A ID20011726 A ID 20011726A ID 30138 A ID30138 A ID 30138A
Authority
ID
Indonesia
Prior art keywords
trisiclic
polymesase
adp
ribose
obstacles
Prior art date
Application number
IDW00200101726A
Other languages
English (en)
Indonesian (id)
Inventor
Stephen E Webber
Stacie S Canan-Koch
Jayashree G Tikhe
Lars H Thoresen
Original Assignee
Agouron Pharma
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Cancer Res Campaign Tech filed Critical Agouron Pharma
Publication of ID30138A publication Critical patent/ID30138A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW00200101726A 1999-01-11 2000-01-19 Penghambat-penghambat trisiklik dari poli (adp-ribose) polimesase ID30138A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11543199P 1999-01-11 1999-01-11

Publications (1)

Publication Number Publication Date
ID30138A true ID30138A (id) 2001-11-08

Family

ID=22361361

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101726A ID30138A (id) 1999-01-11 2000-01-19 Penghambat-penghambat trisiklik dari poli (adp-ribose) polimesase

Country Status (40)

Country Link
US (4) US6495541B1 (xx)
EP (1) EP1140936B1 (xx)
JP (1) JP4093448B2 (xx)
KR (1) KR100632079B1 (xx)
CN (1) CN100418967C (xx)
AP (1) AP1538A (xx)
AT (1) ATE261963T1 (xx)
AU (1) AU781711B2 (xx)
BG (1) BG65210B1 (xx)
BR (1) BRPI0008614B8 (xx)
CA (1) CA2360003C (xx)
CZ (1) CZ302941B6 (xx)
DE (1) DE60009033T2 (xx)
DK (1) DK1140936T3 (xx)
EA (1) EA004989B1 (xx)
EE (1) EE05006B1 (xx)
ES (1) ES2218110T3 (xx)
GE (1) GEP20033055B (xx)
HK (1) HK1040992A1 (xx)
HR (1) HRP20010573B1 (xx)
HU (1) HU229875B1 (xx)
ID (1) ID30138A (xx)
IL (2) IL144112A0 (xx)
IS (1) IS5995A (xx)
LT (1) LT4936B (xx)
LV (1) LV12770B (xx)
MX (1) MXPA01007001A (xx)
NO (1) NO320343B1 (xx)
NZ (1) NZ512731A (xx)
OA (2) OA11749A (xx)
PL (1) PL210415B1 (xx)
PT (1) PT1140936E (xx)
RO (1) RO121778B1 (xx)
RS (1) RS50031B (xx)
SI (1) SI20691B (xx)
SK (1) SK287338B6 (xx)
TR (1) TR200102005T2 (xx)
UA (1) UA75034C2 (xx)
WO (1) WO2000042040A1 (xx)
ZA (1) ZA200105399B (xx)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010087401A (ko) * 1999-09-28 2001-09-15 스타르크, 카르크 아제피노인돌 유도체, 그의 제법 및 용도
US6589725B1 (en) 1999-10-25 2003-07-08 Rigel Pharmaceuticals, Inc. Tankyrase H, compositions involved in the cell cycle and methods of use
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
CZ20023110A3 (cs) * 2000-03-20 2003-02-12 N-Gene Research Laboratories Inc. Deriváty amidoximu propenkarboxylové kyseliny, způsob jejich přípravy a farmaceutické přípravky je obsahující
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
DE60142921D1 (de) * 2000-12-01 2010-10-07 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
US6924284B2 (en) 2001-08-15 2005-08-02 Icos Corporation PARP inhibitors
US20030096833A1 (en) 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2002358650A1 (en) * 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1947102A1 (en) * 2003-01-09 2008-07-23 Pfizer, Inc. Compositions comprising diazepinoindole derivatives as kinase inhibitors
CN100398519C (zh) 2003-02-28 2008-07-02 伊诺泰克制药公司 四环苯甲酰胺衍生物及其用法
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0408996A (pt) * 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
EP1633362B1 (en) * 2003-05-28 2012-09-26 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
KR101138471B1 (ko) * 2003-07-25 2012-04-25 화이자 인코포레이티드 트리시클로 ｐａｒｐ 저해제
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
DK1684736T3 (da) 2003-12-01 2011-11-21 Kudos Pharm Ltd Inhibitorer af DNA-skadereparation til behandling af cancer
JP2007527872A (ja) 2004-02-26 2007-10-04 イノテック ファーマシューティカルズ コーポレイション イソキノリン誘導体及びその使用方法
RU2361592C2 (ru) * 2004-09-22 2009-07-20 Пфайзер Инк. Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы
PL1794163T3 (pl) * 2004-09-22 2010-06-30 Pfizer Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy
CN101133061B (zh) * 2004-09-22 2011-09-07 辉瑞有限公司 8-氟-2-{4-[（甲基氨基）甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,4,3-cd]吲哚-6-酮的磷酸盐的多晶型物和非晶物
ES2382950T3 (es) * 2004-09-22 2012-06-14 Pfizer, Inc. Formas polimorfas de la sal de fosfato de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepin[5,4,3-cd]indol-6-ona
EP1841771A4 (en) 2005-01-19 2008-09-24 Mgi Gp Inc COMPOUNDS OF DIAZABENZO [DE] ANTHRACENE-3-ONE AND USE IN INHIBITION OF PARP
US7381722B2 (en) 2005-02-25 2008-06-03 Inotek Pharmaceuticals Corporation Tetracyclic amino and carboxamido compounds and methods of use thereof
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005022111A1 (de) * 2005-05-12 2006-11-16 Siemens Ag Verfahren zum Datenaustausch
WO2006137510A1 (ja) 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. 脳血管障害時における出血低減剤
EP1910338B1 (en) 2005-07-14 2010-08-25 Irm, Llc Heterotetracyclic compounds as tpo mimetics
EP1906948A4 (en) 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
RU2008110955A (ru) 2005-08-24 2009-09-27 Инотек Фармасьютикалз Корпорейшн (Us) Инденоизохинолиноновые аналоги и способы их применения
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
EP2329818A1 (en) * 2006-01-17 2011-06-08 Abbott Laboratories Combination therapy with PARP inhibitors
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US7994222B2 (en) 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
CA2662517A1 (en) 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
US8119654B2 (en) 2007-02-28 2012-02-21 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
KR20100059950A (ko) 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
BRPI0820518B1 (pt) 2007-10-03 2021-09-28 Eisai Inc Composto e composição farmacêutica
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
KR100986820B1 (ko) * 2010-01-27 2010-10-12 (주)에코베이스 막힘방지형 고효율 산기장치 및 이를 이용한 수질정화장치
EP3150610B1 (en) 2010-02-12 2019-07-31 Pfizer Inc Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
WO2012071684A1 (en) 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivates，preparation processes and medical uses thereof
NZ624063A (en) 2011-12-31 2016-09-30 Beigene Ltd Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
AU2011384859B2 (en) 2011-12-31 2016-03-17 Beigene, Ltd. Fused tetra or penta-cyclic pyridophthalazinones as PARP inhibitors
US9855261B2 (en) 2012-11-08 2018-01-02 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
CA2935857C (en) 2014-01-05 2020-12-15 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
KR20170016498A (ko) 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
CA2955495C (en) 2014-08-22 2023-09-19 Jeffrey Etter High dosage strength tablets of rucaparib
CN105607772B (zh) * 2014-11-13 2020-11-03 现代自动车株式会社 触摸输入装置以及包括该装置的车辆
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CA2977685C (en) 2015-03-02 2024-02-20 Sinai Health System Homologous recombination factors
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
WO2017032289A1 (en) 2015-08-25 2017-03-02 Beigene, Ltd. Process for preparing parp inhibitor, crystalline forms, and uses thereof
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN107286166B (zh) * 2016-04-11 2020-03-31 上海勋和医药科技有限公司 取代1，3，4，5-四氢-6h-吡咯并[4，3，2-ef][2]苯并氮杂-6-酮衍生物
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
TWI806840B (zh) 2016-09-27 2023-07-01 英屬開曼群島商百濟神州有限公司 使用包含parp抑制劑的組合產品治療癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
CN106854172B (zh) * 2016-12-11 2019-04-19 山东轩德医药科技有限公司 一种6-氟-1h-吲哚-4-甲酸甲酯的制备方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
US10875870B2 (en) 2017-01-24 2020-12-29 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
CN106748958B (zh) * 2017-01-25 2018-12-18 伦俊杰 一种Rucaparib中间体的制备方法
WO2018157794A1 (en) 2017-02-28 2018-09-07 Beigene, Ltd. Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
JP7264489B2 (ja) * 2017-05-24 2023-04-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア イメージング及び放射線療法のための放射標識された蛍光性ｐａｒｐ阻害剤
IT201700085789A1 (it) 2017-07-26 2019-01-26 Olon Spa Metodo per la preparazione di rucaparib ad elevata purezza
US20210085796A1 (en) * 2017-07-28 2021-03-25 Yale University Anticancer drugs and methods of making and using same
CN109651377B (zh) * 2017-10-12 2020-10-20 成都海创药业有限公司 一种治疗癌症的化合物及其用途
CN109651376B (zh) * 2017-10-12 2022-06-03 江苏创诺制药有限公司 一种氮杂卓并[5,4,3-cd]吲哚-6-酮化合物的合成方法
CA3080657A1 (en) * 2017-11-03 2019-05-09 Sandoz Ag Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
WO2019115000A1 (en) 2017-12-15 2019-06-20 Advitech Advisory And Technologies Sa Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) * 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
CN110229162B (zh) * 2018-03-05 2020-08-11 新发药业有限公司 一种瑞卡帕布的简便制备方法
CN111819282A (zh) 2018-03-13 2020-10-23 欧恩科斯欧公司 对抗癌症治疗中获得性耐药性的Dbait分子
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
WO2019207596A1 (en) 2018-04-25 2019-10-31 Mylan Laboratories Limited Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base
CN108743557A (zh) * 2018-06-27 2018-11-06 李莉 一种磷酸瑞卡帕布软胶囊及其制备方法
CN108976236B (zh) * 2018-08-16 2020-11-10 湖南华腾制药有限公司 一种氘代parp抑制剂、其盐、其制备方法及用途
CN111217818A (zh) * 2018-11-27 2020-06-02 台耀化学股份有限公司 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
SG11202108399PA (en) * 2019-02-02 2021-09-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Indolo heptamyl oxime analogue as parp inhibitor
CN110256468B (zh) * 2019-05-14 2020-09-01 山东省分析测试中心 双吲哚生物碱化合物或其药学上可接受的盐及其制备方法和应用
JP7370032B2 (ja) 2019-05-14 2023-10-27 スーヂョウ フォー ヘルス ファーマスーティカルズ カンパニー リミテッド Ｐａｒｒ阻害剤としてのキナゾリン―２．４―ジオン誘導体
JP2022541749A (ja) 2019-07-10 2022-09-27 サイブレクサ ２，インコーポレイテッド 治療薬としての細胞毒素のペプチドコンジュゲート
KR20220051332A (ko) 2019-07-10 2022-04-26 싸이브렉사 3, 인크. 치료제로서의 미세소관 표적화제의 펩티드 접합체
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021156140A1 (en) 2020-02-03 2021-08-12 Sandoz Ag Polymorph of rucaparib mesylate
CN113288892B (zh) 2020-02-24 2024-04-26 甫康（上海）健康科技有限责任公司 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用
WO2021220120A1 (en) 2020-04-28 2021-11-04 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
CN111646990B (zh) * 2020-05-22 2023-01-10 同济大学 一种3,4-桥环吲哚类化合物的制备方法及Rucaparib的合成方法
CN111662299B (zh) * 2020-07-10 2022-07-26 中山大学 一种取代吲哚并氮杂酮类化合物及其制备方法和应用
WO2022015557A1 (en) 2020-07-14 2022-01-20 Assia Chemical Industries Ltd Solid state forms of rucaparib salts
US20230331739A1 (en) * 2020-07-31 2023-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1（2h）-酮及其合成方法
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
US20240093250A1 (en) 2021-01-08 2024-03-21 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
CN117321044A (zh) 2021-04-08 2023-12-29 理森制药股份公司 聚(adp-核糖)聚合酶抑制剂
EP4342898A1 (en) * 2021-05-18 2024-03-27 Onconic Therapeutics Inc. Crystalline form of tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642820A (en) 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
DE2322434A1 (de) 1973-05-04 1974-11-21 Bayer Ag 2-trifluormethylimino-1,3-dithioloeckige klammer auf 4,5-b eckige klammer zu -chinoxaline, verfahren zu ihrer herstellung, sowie ihre verwendung als insektizide, akarizide und fungizide
US4033960A (en) 1973-07-31 1977-07-05 Bayer Aktiengesellschaft 2-Mercaptoquinoxaline-di-N-oxide products and a method for their preparation
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3959343A (en) * 1974-10-25 1976-05-25 Wako Pure Chemical Industries, Ltd. Process for producing hydrazonitriles
DE2913728A1 (de) 1979-04-05 1980-10-16 Bayer Ag 2-sulfonyl-chinoxaline, verfahren zu ihrer herstellung sowie ihre verwendung als mikrobizide
DE3103137A1 (de) 1981-01-30 1982-08-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung aliphatischer cyclischer kohlensaeureester
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
JPS6434988A (en) * 1987-07-30 1989-02-06 Kissei Pharmaceutical Azepinoindole derivative
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9117987D0 (en) 1991-08-20 1991-10-09 Ici Plc Heterocyclic compounds
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
WO1995009159A1 (en) 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
DE69624115T2 (de) 1995-08-02 2003-06-18 Newcastle University Ventures Ltd., Jesmond Benzimidazol verbindungen
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
AU745790B2 (en) 1997-05-13 2002-03-28 Octamer, Inc. Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
WO1999059975A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19946289A1 (de) 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
KR20010087401A (ko) 1999-09-28 2001-09-15 스타르크, 카르크 아제피노인돌 유도체, 그의 제법 및 용도

Also Published As

Publication number Publication date
BR0008614A (pt) 2001-10-16
OA11749A (en) 2005-07-19
EA004989B1 (ru) 2004-10-28
NZ512731A (en) 2004-01-30
SI20691A (sl) 2002-04-30
HRP20010573A2 (en) 2005-02-28
AU2408800A (en) 2000-08-01
RS50031B (sr) 2008-11-28
PT1140936E (pt) 2004-06-30
NO20013313L (no) 2001-09-10
LT4936B (lt) 2002-07-25
BG65210B1 (bg) 2007-07-31
GEP20033055B (en) 2003-08-25
MXPA01007001A (es) 2002-07-30
SK9662001A3 (en) 2002-04-04
EP1140936B1 (en) 2004-03-17
HUP0105414A3 (en) 2003-04-28
NO320343B1 (no) 2005-11-28
EE05006B1 (et) 2008-04-15
KR20020008112A (ko) 2002-01-29
OA12185A (en) 2006-05-09
HU229875B1 (en) 2014-11-28
SI20691B (sl) 2008-10-31
NO20013313D0 (no) 2001-07-04
IL144112A (en) 2006-07-05
IL144112A0 (en) 2002-05-23
BR0008614B1 (pt) 2014-11-25
CA2360003C (en) 2012-07-10
US20030078254A1 (en) 2003-04-24
LT2001083A (en) 2002-03-25
PL357049A1 (en) 2004-07-12
BG105811A (en) 2002-05-31
US20060009517A1 (en) 2006-01-12
CN100418967C (zh) 2008-09-17
DK1140936T3 (da) 2004-06-21
EP1140936A1 (en) 2001-10-10
HK1040992A1 (en) 2002-06-28
US6977298B2 (en) 2005-12-20
IS5995A (is) 2001-07-10
BRPI0008614B8 (pt) 2021-05-25
SK287338B6 (sk) 2010-07-07
CN1342161A (zh) 2002-03-27
UA75034C2 (en) 2006-03-15
EA200100764A1 (ru) 2002-06-27
AU781711B2 (en) 2005-06-09
KR100632079B1 (ko) 2006-10-04
LV12770A (en) 2001-12-20
US7429578B2 (en) 2008-09-30
TR200102005T2 (tr) 2001-12-21
CA2360003A1 (en) 2000-07-20
WO2000042040A1 (en) 2000-07-20
LV12770B (lv) 2002-05-20
CZ302941B6 (cs) 2012-01-25
DE60009033T2 (de) 2004-08-05
CZ20012443A3 (cs) 2002-02-13
AP2001002211A0 (en) 2001-09-30
YU49001A (sh) 2005-11-28
DE60009033D1 (de) 2004-04-22
ATE261963T1 (de) 2004-04-15
AP1538A (en) 2006-01-10
EE200100364A (et) 2002-10-15
ES2218110T3 (es) 2004-11-16
JP2002534523A (ja) 2002-10-15
US6495541B1 (en) 2002-12-17
HUP0105414A2 (hu) 2002-05-29
ZA200105399B (en) 2002-07-01
RO121778B1 (ro) 2008-04-30
JP4093448B2 (ja) 2008-06-04
HRP20010573B1 (en) 2006-04-30
PL210415B1 (pl) 2012-01-31
US20050085460A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
ID30138A (id) Penghambat-penghambat trisiklik dari poli (adp-ribose) polimesase
ATE281036T1 (de) Kommunikationsverfahren
DE69805443D1 (de) Sachet-formulierungen
DE60044131D1 (de) Katheter
DE60110982D1 (de) Wasserdichter Verbinder
DE60128525D1 (de) Wasserdichter Verbinder
DE60015014D1 (de) Wasserdichter Steckverbinder
DE60013709D1 (de) Kopfhörer
DE60109529D1 (de) Wasserdichter Steckverbinder
DE60000356D1 (de) Haltebügel
DE60010632D1 (de) Steckverbinder
DE60027329D1 (de) Biokompatible katheter
DE60043338D1 (de) Verbindungselement
IT1316763B1 (it) Differenziale
DE60021023D1 (de) Wasserdichter Verbinder
DE60105533D1 (de) Wasserdichter Verbinder
DE60023789D1 (de) Drehbarer Verbinder
DE60042437D1 (de) Wasserdichter Steckverbinder
DE60212519D1 (de) Wasserdichter Verbinder
DE60104250D1 (de) Wasserdichter Verbinder
ID30023A (id) Kombinasi senyawa aktif fungisida
DE50115568D1 (de) Kinnbügel-Kopfhörer
NO20003809L (no) Kopling
DE60001169D1 (de) Kabelverbinder
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner